BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

879 related articles for article (PubMed ID: 20701289)

  • 21. Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening.
    Tournier N; Valette H; Peyronneau MA; Saba W; Goutal S; Kuhnast B; Dollé F; Scherrmann JM; Cisternino S; Bottlaender M
    J Nucl Med; 2011 Mar; 52(3):415-23. PubMed ID: 21321274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
    Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
    Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate.
    Oostendorp RL; Marchetti S; Beijnen JH; Mazzanti R; Schellens JH
    Cancer Chemother Pharmacol; 2007 May; 59(6):855-60. PubMed ID: 17180388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.
    Ma L; Qin Y; Shen Z; Bi H; Hu H; Huang M; Zhou H; Yu L; Jiang H; Zeng S
    J Ethnopharmacol; 2015 Aug; 172():430-5. PubMed ID: 26183576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
    Dahan A; Amidon GL
    Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells.
    Svirnovski AI; Shman TV; Serhiyenka TF; Savitski VP; Smolnikova VV; Fedasenka UU
    Hematology; 2009 Aug; 14(4):204-12. PubMed ID: 19635183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2.
    Shukla S; Sauna ZE; Ambudkar SV
    Leukemia; 2008 Feb; 22(2):445-7. PubMed ID: 17690695
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of oxygen on multidrug resistance in the first trimester human placenta.
    Lye P; Bloise E; Dunk C; Javam M; Gibb W; Lye SJ; Matthews SG
    Placenta; 2013 Sep; 34(9):817-23. PubMed ID: 23790363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
    Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
    Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression.
    Nakanishi T; Shiozawa K; Hassel BA; Ross DD
    Blood; 2006 Jul; 108(2):678-84. PubMed ID: 16543472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression.
    Turrini E; Haenisch S; Laechelt S; Diewock T; Bruhn O; Cascorbi I
    Pharmacogenet Genomics; 2012 Mar; 22(3):198-205. PubMed ID: 22241070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).
    Römermann K; Helmer R; Löscher W
    Neuropharmacology; 2015 Jun; 93():7-14. PubMed ID: 25645391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of expression and activity of multidrug resistance proteins MRP2 and MDR1 by estrogenic compounds in Caco-2 cells. Role in prevention of xenobiotic-induced cytotoxicity.
    Arias A; Rigalli JP; Villanueva SS; Ruiz ML; Luquita MG; Perdomo VG; Vore M; Catania VA; Mottino AD
    Toxicology; 2014 Jun; 320():46-55. PubMed ID: 24685904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.
    Wang L; Giannoudis A; Lane S; Williamson P; Pirmohamed M; Clark RE
    Clin Pharmacol Ther; 2008 Feb; 83(2):258-64. PubMed ID: 17568400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of thiazolidinediones (glitazones) with the ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein.
    Weiss J; Sauer A; Herzog M; Böger RH; Haefeli WE; Benndorf RA
    Pharmacology; 2009; 84(5):264-70. PubMed ID: 19776663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).
    Merino G; Jonker JW; Wagenaar E; Pulido MM; Molina AJ; Alvarez AI; Schinkel AH
    Drug Metab Dispos; 2005 May; 33(5):614-8. PubMed ID: 15703302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
    Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A model of secreting murine mammary epithelial HC11 cells comprising endogenous Bcrp/Abcg2 expression and function.
    Tallkvist J; Yagdiran Y; Danielsson L; Oskarsson A
    Cell Biol Toxicol; 2015 Apr; 31(2):111-20. PubMed ID: 25791223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Celecoxib sensitizes imatinib-resistant K562 cells to imatinib by inhibiting MRP1-5, ABCA2 and ABCG2 transporters via Wnt and Ras signaling pathways.
    Dharmapuri G; Doneti R; Philip GH; Kalle AM
    Leuk Res; 2015 Jul; 39(7):696-701. PubMed ID: 25916699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.